Pre-therapeutic LDH, HB, CRP, ALP and GGT level are helpful parameters for prediction of overall survival of patients receiving Lu-177-PSMA-617-RLT for metastasized prostate cancer. This evidence concerns the gene FOLH1 and Familial prostate cancer.